Skip to main content

Table 3 Survival parameters - CR versus non CR after ASCT. Patients ≤ 60 years. Number of patients evaluable for treatment response = 176

From: Improved outcome in patients following autologous stem cell transplantation for multiple myeloma in south eastern Norway 2001–2010: a retrospective, population based analysis

 

Median Overall Survival (Months) (95% CI)

Median Time to New Treatment (Months) (95% CI)

CR1

Non CR2

P- value

CR

Non CR

P-value

Period 13 (N = 69)

92.3 (33.1–151.6)

56.1 (39.1–73.1)

P = 0.04

45.4 (7.0–110.3)

36.6 (31.3–42.0)

P = 0.001

Period 24 (N = 107)

Not reacheda

81.0 (76.1–113.3)

P = 0.001

49.7 (8.4–91.0)

29.4 (25.6–33.2)

P = 0.001

Period 1 + 2 (N = 176)

133.7 (80.6–186.9)

79.3 (62.2–96.3)

P = 0.001

49.7 (19.2–80.1)

31.3 (25.2–37.3)

P = 0.001

  1. aMean overall survival = 112.3 months (95% CI 99.7–124.4)
  2. 1Number of CR patients: Period 1: 24/69 Period 2: 33/107
  3. 2Number of non CR patients Period 1: 45/69 Period 2: 74/107
  4. 3Period 1 = 01.01.2001–31.06.2005
  5. 4Period 2 = 01.07.2005–31.12.2009
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us